Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Chime Biologics, a leading CDMO that enables its partners’ success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage biotech company, announced on September 28 that the companies are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115. Under…